Identification Of Potential Toxoplasma Gondii cDNA Phage Clones And Production Of The Corresponding Recombinant Proteins In The Development Of IgG Avidity Assay For Serodiagnosis Of Toxoplasmosis by Teh, Ai Ying
  
IDENTIFICATION OF POTENTIAL  
Toxoplasma gondii cDNA PHAGE CLONES AND 
PRODUCTION OF THE CORRESPONDING 
RECOMBINANT PROTEINS IN THE 
DEVELOPMENT OF IgG AVIDITY ASSAY FOR 
SERODIAGNOSIS OF TOXOPLASMOSIS 
 
 
 
 
 
 
 
 
 
TEH AI YING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2016 
 
  
IDENTIFICATION OF POTENTIAL  
Toxoplasma gondii cDNA PHAGE CLONES AND 
PRODUCTION OF THE CORRESPONDING 
RECOMBINANT PROTEINS IN THE 
DEVELOPMENT OF IgG AVIDITY ASSAY FOR 
SERODIAGNOSIS OF TOXOPLASMOSIS 
 
 
 
by 
 
 
 
TEH AI YING 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements 
for the degree of  
Doctor of Philosophy 
 
 
July 2016 
 ii 
 
ACKNOWLEDGEMENT 
I wish to express my deepest gratitude to my supervisor, Professor Dr. Rahmah 
Noordin, for her excellent guidance, supervision, and continuous support all along 
this study despite her many other academic commitments. Her professional advice, 
suggestions, and comments have inspired me and led to the completion of this study.  
My deepest appreciation goes to Dr. Atefeh, Dr. Syahida, Sin Yee, Izzati and 
Dr. Nurulhasanah Othman for their valuable advice and guidance throughout my 
study. I would like to thank the members of the research laboratory, Hafinur, 
Syazwan, Chang, Sabariah, Anizah, Nad and Izan for their co-operation, moral 
support and idea-sharing throughout the years. My gratitude also goes to the 
administrative staff, Fauziah, Irwan, Nurul’ Jannah, Hafriz, Iman, Mazni, Omar, 
Adli, Azizi, Siti and Azam who have been always helpful and supportive. I am also 
thankful to INFORMM lecturers for their valuable comments and suggestions. 
Sincere thanks go to my fellow schoolmates and friends for their assistance and 
encouragement. Throughout the study, I have gained precious experiences and 
unforgettable memories.   
Last but not least, my gratitude goes to my beloved husband and family 
members for their love, support and constant encouragement throughout my study. I 
am grateful to have their understanding and deeply sorry for the time we spent apart.  
I truly appreciate the Universiti Sains Malaysia (USM) fellowship I received 
from the university for 3 consecutive years. This study was mainly funded by 
Science Fund, grant no. 02-01-05-SF0428 from the Ministry of Science, Technology 
and Innovation Malaysia and partly by Universiti Sains Malaysia RU-PRGS grant 
with no. 1001/CIPPM/846044.  
 
 iii 
 
TABLE OF CONTENTS 
                                                                                                                                 
ACKNOWLEDGEMENT ......................................................................................... ii 
TABLE OF CONTENTS .......................................................................................... iii 
LIST OF TABLES ................................................................................................... xii 
LIST OF FIGURES ................................................................................................ xiv 
LIST OF ABBREVIATIONS ............................................................................... xvii 
ABSTRAK ............................................................................................................. xviii 
ABSTRACT .............................................................................................................. xx 
CHAPTER 1 INTRODUCTION .............................................................................. 1 
1.1 Toxoplasma gondii and toxoplasmosis .......................................................... 1 
1.2 Taxonomy of T. gondii .................................................................................. 2 
1.3 Stages and morphology of T. gondii .............................................................. 2 
1.3.1 Tachyzoite ............................................................................................ 5 
1.3.2 Bradyzoite............................................................................................. 6 
1.3.3 Sporozoite ............................................................................................. 6 
1.4 Life cycle of T. gondii .................................................................................... 7 
1.5 Epidemiology ............................................................................................... 10 
1.6 Transmission ................................................................................................ 13 
1.6.1 Congenital........................................................................................... 13 
1.6.2 Foodborne ........................................................................................... 14 
1.6.3 Animal-to-human (zoonotic) .............................................................. 15 
1.6.4 Others ................................................................................................. 16 
1.7 Pathogenesis of toxoplasmosis .................................................................... 17 
1.8 Immune response ......................................................................................... 18 
1.9 Clinical presentations of toxoplasmosis....................................................... 21 
1.9.1 Immunocompetent individuals ........................................................... 21 
1.9.2 Congenital toxoplasmosis ................................................................... 23 
1.9.3 Immunocompromised patients ........................................................... 24 
1.10 Diagnosis of toxoplasmosis ......................................................................... 28 
1.10.1 Direct detection and isolation of T. gondii parasites ....................... 28 
1.10.2 Molecular analysis ........................................................................... 28 
1.10.3 Serological tests ............................................................................... 30 
1.10.3(a) Sabin-Feldman dye test (DT) .......................................... 30 
 iv 
 
1.10.3(b) Indirect immunofluorescence antibody assay (IFA) ....... 31 
1.10.3(c) Agglutination assays ........................................................ 32 
1.10.3(d) Enzyme-linked immunosorbent assay (ELISA) .............. 34 
1.10.3(e) Western blot assay ........................................................... 35 
1.10.3(f) IgG avidity assay ............................................................. 36 
1.10.3(g) Toxoplasma serological profile (TSP) ............................. 37 
1.11 Prevention and control ................................................................................. 38 
1.12 Treatment ..................................................................................................... 40 
1.13 Statement of the problem and rationale of the study ................................... 41 
1.14 Objectives of the study................................................................................. 43 
CHAPTER 2 MATERIALS AND METHODS ..................................................... 45 
2.1 Study design ................................................................................................. 45 
2.2 Materials ...................................................................................................... 49 
2.2.1 Common buffers and reagents ............................................................ 49 
2.2.1(a) Phosphate-buffered saline (PBS) ..................................... 49 
2.2.1(b) PBS-Tween 20 (PBST) .................................................... 49 
2.2.1(c) Luria-Bertani (LB) broth ................................................. 49 
2.2.1(d) Tris-buffered Saline (TBS) .............................................. 50 
2.2.1(e) TBS-Tween 20 (TBST) ................................................... 50 
2.2.1(f) Tetracycline (10 mg/ml) .................................................. 50 
2.2.1(g) Ampicillin (100 mg/ml) ................................................... 50 
2.2.1(h) Kanamycin (50 mg/ml) .................................................... 50 
2.2.2 Reagents for serum pre-adsorption ..................................................... 51 
2.2.2(a) 20% (w/v) maltose ........................................................... 51 
2.2.2(b) 1M MgSO4 ....................................................................... 51 
2.2.2(c) LB broth with supplements.............................................. 51 
2.2.2(d) Microsphere beads ........................................................... 51 
2.2.2(e) LB-tetracycline broth ....................................................... 52 
2.2.2(f) Lysis buffer ...................................................................... 52 
2.2.2(g) Protease inhibitor ............................................................. 52 
2.2.2(h) Lysozyme......................................................................... 52 
2.2.2(i) Washing solution for microsphere beads ......................... 53 
2.2.2(j) Blocking solution for microsphere beads ........................ 53 
2.2.2(k) Reducing agent and detergent compatible (RC 
DC
TM
)
 
protein assay ......................................................... 53 
 v 
 
2.2.3 Reagents for Indirect Enzyme-Linked Immunosorbent Assay 
(ELISA) ........................................................................................... 53 
2.2.3(a) Coating buffer .................................................................. 53 
2.2.3(b) Washing solution ............................................................. 53 
2.2.3(c) Blocking solution (3% BSA) ........................................... 54 
2.2.3(d) Primary antibody ............................................................. 54 
2.2.3(e) Secondary antibody ......................................................... 54 
2.2.3(f) ABTS substrate solution .................................................. 54 
2.2.4 Reagents for Toxoplasma gondii cDNA clones amplification ........... 54 
2.2.4(a) Bacterial host strain ......................................................... 54 
2.2.4(b) LB broth with supplements.............................................. 55 
2.2.4(c) LB agar ............................................................................ 55 
2.2.4(d) NZY broth........................................................................ 55 
2.2.4(e) NZY agar ......................................................................... 55 
2.2.4(f) NZY top agar ................................................................... 56 
2.2.4(g) SM buffer ......................................................................... 56 
2.2.5 Reagents for cDNA clones immunoscreening and avidity 
immunoscreening ............................................................................. 56 
2.2.5(a) Washing solution ............................................................. 56 
2.2.5(b) Blocking solution ............................................................. 56 
2.2.5(c) Isopropyl-beta-D-thiogalactopyranoside (IPTG) ............ 56 
2.2.5(d) Nitrocellulose filter membrane ........................................ 57 
2.2.5(e) Primary antibody ............................................................. 57 
2.2.5(f) Secondary antibody ......................................................... 57 
2.2.5(g) Chemiluminescence substrate.......................................... 57 
2.2.5(h) Developer ......................................................................... 57 
2.2.5(i) Fixer ................................................................................. 58 
2.2.5(j) X-ray film ........................................................................ 58 
2.2.5(k) Urea solution.................................................................... 58 
2.2.6 Reagents for phage plasmid extraction and analysis .......................... 58 
2.2.6(a) LB broth with ampicillin ................................................. 58 
2.2.6(b) TBE buffer ....................................................................... 58 
2.2.6(c) Ethidium bromide (EtBr) solution ................................... 59 
2.2.6(d) Loading buffer (6X) ......................................................... 59 
2.2.7 Reagents for real-time quantitative PCR analysis .............................. 59 
2.2.7(a) Toxoplasma gondii grown in-vivo and in-vitro ............... 59 
 vi 
 
2.2.7(b) RNA preparation.............................................................. 59 
2.2.7(c) cDNA preparation ............................................................ 59 
2.2.7(d) Real-time PCR ................................................................. 60 
2.2.8 Reagents for cloning and transformation ........................................... 60 
2.2.8(a) Magnesium chloride (MgCl2, 100mM) ........................... 60 
2.2.8(b) Calcium chloride (CaCl2, 100mM) .................................. 60 
2.2.8(c) LB-ampicillin agar plates ................................................ 60 
2.2.9 Reagents for expression of recombinant proteins .............................. 60 
2.2.9(a) Terrific broth (TB) ........................................................... 60 
2.2.9(b) Salt solution ..................................................................... 61 
2.2.9(c) Lysis buffer ...................................................................... 61 
2.2.9(d) Protease inhibitor and lysozyme ...................................... 61 
2.2.10 Reagents for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) .......................................................... 61 
2.2.10(a) Resolving gel buffer ........................................................ 61 
2.2.10(b) Stacking buffer ................................................................ 62 
2.2.10(c) SDS sample buffer (5X) .................................................. 62 
2.2.10(d) Ammonium persulfate (APS) .......................................... 62 
2.2.10(e) Running buffer ................................................................. 62 
2.2.10(f) Staining solution .............................................................. 62 
2.2.10(g) Destaining solution .......................................................... 63 
2.2.11 Reagents for western blot ................................................................ 63 
2.2.11(a) Transfer buffer ................................................................. 63 
2.2.11(b) Washing solution ............................................................. 63 
2.2.11(c) Blocking solution ............................................................. 63 
2.2.11(d) Anti-His antibody ............................................................ 63 
2.2.11(e) Chemiluminescence substrate, developer, fixer and 
X-ray film ........................................................................ 64 
2.2.12 Reagents for protein extraction ........................................................ 64 
2.2.12(a) Lysis buffer ...................................................................... 64 
2.2.12(b) Protease inhibitor and lysozyme ...................................... 64 
2.2.13 Reagents for protein purification under native conditions .............. 64 
2.2.13(a) Lysis buffer ...................................................................... 64 
2.2.13(b) DNase I ............................................................................ 64 
2.2.13(c) Washing buffer, 20 mM imidazole .................................. 65 
2.2.13(d) Washing buffer, 30 mM imidazole .................................. 65 
 vii 
 
2.2.13(e) Washing buffer, 40 mM imidazole .................................. 65 
2.2.13(f) Elution buffer ................................................................... 65 
2.2.13(g) Dye reagent concentrated protein assay .......................... 66 
2.2.14 Reagents for protein purification under denaturing conditions ....... 66 
2.2.14(a) Buffer B ........................................................................... 66 
2.2.14(b) Buffer C ........................................................................... 66 
2.2.14(c) Buffer D ........................................................................... 66 
2.2.14(d) Buffer E ........................................................................... 66 
2.2.14(e) Dye reagent concentrated protein assay .......................... 67 
2.2.15 Reagents for IgG avidity western blot ............................................. 67 
2.2.15(a) Transfer buffer ................................................................. 67 
2.2.15(b) Blocking solution ............................................................. 67 
2.2.15(c) Washing solution ............................................................. 67 
2.2.15(d) Primary and secondary antibodies ................................... 67 
2.2.15(e) Chemiluminescence substrate, developer, fixer, and 
film................................................................................... 67 
2.2.15(f) Urea solution.................................................................... 67 
2.2.16 IgG avidity ELISA ........................................................................... 68 
2.2.16(a) Coating buffer .................................................................. 68 
2.2.16(b) Washing solution ............................................................. 68 
2.2.16(c) Blocking solution ............................................................. 68 
2.2.16(d) Primary and secondary antibodies ................................... 68 
2.2.16(e) ABTS substrate solution .................................................. 68 
2.2.16(f) Urea solution.................................................................... 68 
2.3 Methodology ................................................................................................ 69 
2.3.1 Screening and classification of serum samples .................................. 69 
2.3.1(a) Serum samples used in immunoscreening and 
avidity immunoscreening ................................................ 70 
2.3.1(b) Serum samples used in IgG avidity western blot and 
IgG avidity ELISA........................................................... 70 
2.3.2 Toxoplasma gondii cDNA phage clones ............................................ 70 
2.3.3 Serum pre-adsorption ......................................................................... 71 
2.3.3(a) Preparation of E. coli XL1-Blue MRF’ whole cell 
pellet ................................................................................ 71 
2.3.3(b) Preparation of E. coli XL1-Blue MRF’ cell lysate .......... 72 
2.3.3(c) Determination of protein concentration by RC DCTM 
method ............................................................................. 72 
 viii 
 
2.3.3(d) Coating of microsphere beads with E. coli XL1-Blue 
MRF’ cell lysate .............................................................. 73 
2.3.3(e) Procedure of serum pre-adsorption.................................. 73 
2.3.3(f) Assessment of serum pre-adsorption using indirect 
Enzyme-linked Immunosorbent Assay (ELISA) ............. 74 
2.3.4 T. gondii cDNA phage clones amplification ...................................... 75 
2.3.4(a) Bacteria-host strain dilution ............................................. 75 
2.3.4(b) Amplification procedure of T. gondii cDNA phage 
clones ............................................................................... 75 
2.3.5 Immunoscreening of T. gondii cDNA phage clones .......................... 76 
2.3.5(a) Optimization of the dilution of T. gondii cDNA 
phage clones .................................................................... 76 
2.3.5(b) Optimization of the dilution of primary and 
secondary antibodies ........................................................ 76 
2.3.5(c) Immunoscreening ............................................................ 77 
2.3.5(d) Visualization of signal by chemiluminescence 
substrate ........................................................................... 77 
2.3.5(e) Interpretation of immunoscreening results ...................... 78 
2.3.6 IgG avidity immunoscreening of T. gondii cDNA phage clones ....... 78 
2.3.6(a) Optimization of urea molarity ......................................... 78 
2.3.6(b) IgG avidity immunoscreening ......................................... 79 
2.3.6(c) Visualization of signal by chemiluminescence 
substrate ........................................................................... 79 
2.3.6(d) Interpretation of IgG avidity immunoscreening 
results ............................................................................... 79 
2.3.7 Phage plasmids extraction and analysis ............................................. 80 
2.3.7(a) In-vivo excision ................................................................ 80 
2.3.7(b) Plasmid extraction ........................................................... 81 
2.3.7(c) Determination of concentration and purity of the 
extracted plasmids ........................................................... 82 
2.3.7(d) Agarose gel electrophoresis ............................................. 82 
2.3.7(e) DNA sequencing and data analysis ................................. 83 
2.3.8 Real-time quantitative PCR analysis .................................................. 83 
2.3.8(a) T. gondii RNA extraction ................................................ 84 
2.3.8(b) Synthesis of T. gondii cDNA ........................................... 85 
2.3.8(c) Real-time quantitative PCR using SYBR Green 
probe ................................................................................ 85 
2.3.8(d) Interpretation of real-time quantitative PCR results ........ 86 
 ix 
 
2.3.9 Gene cloning and recombinant plasmid ............................................. 87 
2.3.10 Plasmid transformation into host cells ............................................. 88 
2.3.10(a) Preparation of E. coli competent cells ............................. 88 
2.3.10(b) Cell transformation .......................................................... 88 
2.3.10(c) Plasmid extraction ........................................................... 89 
2.3.11 Expression of histidine (His)-tagged recombinant proteins ............ 89 
2.3.11(a) Preparation of overnight culture of recombinant 
bacteria ............................................................................. 89 
2.3.11(b) Optimization of induction period .................................... 90 
2.3.11(c) Determination of the recombinant protein solubility ...... 90 
2.3.12 Recombinant protein analysis .......................................................... 91 
2.3.12(a) Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis ............................ 91 
2.3.12(a)(i) Gel cassette assembly ............................................ 91 
2.3.12(a)(ii) Preparation of separating gel ................................. 91 
2.3.12(a)(iii) Preparation of stacking gel .................................... 92 
2.3.12(a)(iv) Preparation of protein sample ................................ 92 
2.3.12(a)(v) Electrophoresis ...................................................... 92 
2.3.12(a)(vi) Visualization of protein on SDS-PAGE gel .......... 93 
2.3.12(b) Western blot analysis ....................................................... 94 
2.3.12(b)(i) Protein transfer using semi-dry system ................. 94 
2.3.12(b)(ii) Western blot with HRP-conjugated anti-His 
antibody ........................................................................... 94 
2.3.13 Purification of recombinant proteins ............................................... 95 
2.3.13(a) Native purification ........................................................... 95 
2.3.13(b) Denaturing purification .................................................... 96 
2.3.13(c) Buffer exchange ............................................................... 97 
2.3.14 Protein identification by MALDI-TOF/TOF ................................... 97 
2.3.15 Development and evaluation of recombinant antigens with IgG 
avidity western blot ......................................................................... 98 
2.3.15(a) Optimization of protein concentration and urea 
molarity ............................................................................ 98 
2.3.15(b) IgG avidity western blot .................................................. 98 
2.3.15(c) Interpretation of IgG avidity western blot results ............ 98 
2.3.16 Development and evaluation of recombinant antigens with IgG 
avidity ELISA .................................................................................. 99 
2.3.16(a) Optimization of various parameters ................................ 99 
 x 
 
2.3.16(b) IgG avidity ELISA......................................................... 100 
2.3.16(c) Interpretation of IgG avidity ELISA results .................. 101 
CHAPTER 3 RESULTS ........................................................................................ 102 
3.1 Serum pre-adsorption ................................................................................. 102 
3.2 Optimization of T. gondii cDNA phage dilution ....................................... 105 
3.3 Immunoscreening and avidity immunoscreening ...................................... 107 
3.3.1 Optimizations of primary and secondary antibodies dilutions ......... 107 
3.3.2 Immunoscreening of T. gondii cDNA phage clones ........................ 110 
3.3.3 IgG avidity determined by IgG avidity immunoscreening ............... 114 
3.3.3(a) Optimization of urea molarity ....................................... 114 
3.3.3(b) IgG avidity immunoscreening ....................................... 117 
3.4 Clone identification by phage plasmid extraction and analysis ................. 121 
3.4.1 Clone AG12b .................................................................................... 121 
3.4.1(a) Agarose gel electrophoresis of extracted plasmid 
samples .......................................................................... 121 
3.4.1(b) DNA sequences analysis ............................................... 123 
3.4.2 Clone AG18 ...................................................................................... 126 
3.4.2(a) Agarose gel electrophoresis of extracted plasmid 
samples .......................................................................... 126 
3.4.2(b) DNA sequences analysis ............................................... 126 
3.5 Real-time quantitative PCR analysis ......................................................... 132 
3.5.1 Concentration and purity of T. gondii RNA and cDNA ................... 132 
3.5.2 Real-time quantitative PCR using SYBR Green probe .................... 132 
3.6 Recombinant plasmid................................................................................. 140 
3.6.1 Recombinant plasmid AG12b-pET32 .............................................. 140 
3.6.2 Recombinant plasmid AG18-pET32 ................................................ 143 
3.7 Expression and purification of recombinant protein rAG12b .................... 147 
3.7.1 Optimization of induction period and protein solubility test............ 147 
3.7.2 Purification of His-tagged rAG12b with native condition ............... 149 
3.7.3 Buffer exchange of rAG12b ............................................................. 151 
3.7.4 MALDI-TOF/TOF analysis for rAG12b .......................................... 151 
3.8 Expression and purification of recombinant protein rAG18 ...................... 153 
3.8.1 Optimization of induction period and protein solubility test............ 153 
3.8.2 Purification of His-tagged rAG18 with denaturing condition .......... 155 
3.8.3 Buffer exchange of rAG18 ............................................................... 157 
 xi 
 
3.8.4 MALDI-TOF/TOF analysis for rAG18 ............................................ 157 
3.9 Evaluation of recombinant protein rAG12b .............................................. 159 
3.9.1 Development of IgG avidity western blot utilizing rAG12b ............ 159 
3.9.1(a) Optimization of protein concentration and urea 
molarity .......................................................................... 159 
3.9.1(b) Diagnostic value of rAG12b in IgG avidity western 
blot ................................................................................. 163 
3.9.2 Development of IgG avidity ELISA utilizing rAG12b .................... 166 
3.9.2(a) Optimization of various parameters .............................. 166 
3.9.2(b) Diagnostic value of rAG12b in IgG avidity ELISA ...... 169 
3.10 Evaluation of recombinant protein rAG18 ................................................ 171 
3.10.1 Development of IgG avidity western blot utilizing rAG18 ........... 171 
3.10.1(a) Optimization of protein concentration and urea 
molarity .......................................................................... 171 
3.10.1(b) Diagnostic value of rAG18 in IgG avidity western 
blot ................................................................................. 175 
3.10.2 Development of IgG avidity ELISA utilizing rAG18 ................... 178 
3.10.2(a) Optimization of various parameters .............................. 178 
3.10.2(b) Diagnostic value of rAG18 in IgG avidity ELISA ........ 181 
CHAPTER 4 DISCUSSION .................................................................................. 183 
CONCLUSION ....................................................................................................... 206 
REFERENCES ....................................................................................................... 208 
APPENDICES ........................................................................................................ 227 
  
 
 
 
 
 
 
 
 xii 
 
LIST OF TABLES 
        Page 
Table 1.1 Frequency of symptoms in immunocompetent people with 
acquired toxoplasmosis (Dubey, 2009). ............................................. 22 
Table 1.2 Clinical presentations in untreated congenital toxoplasmosis 
patients (McLeod et al., 2009). .......................................................... 25 
Table 3.1 Serum sample groups used in the serum pre-adsorption. ................. 103 
Table 3.2 Immunoscreening results of T. gondii cDNA phage clones. ............ 111 
Table 3.3 IgG avidity immunoscreeening results of selected T. gondii 
cDNA phage clones. ......................................................................... 118 
Table 3.4 Concentration and purity of extracted plasmid samples of clones 
AG12b and AG18. ............................................................................ 122 
Table 3.5 Self-designed primers for AG12b in DNA sequencing. ................... 124 
Table 3.6  Self-designed primers for AG18 in DNA sequencing. ..................... 128 
Table 3.7 Concentration and purity assessment of extracted T. gondii 
RNA. ................................................................................................. 133 
Table 3.8 Concentration and purity assessment of synthesized T. gondii 
cDNA. ............................................................................................... 133 
Table 3.9 Self-designed primers for AG12b-real time PCR and AG18-real 
time PCR. ......................................................................................... 133 
Table 3.10 Fold change value of AG12b obtained by real-time PCR. ............... 136 
Table 3.11 Fold change value of AG18 obtained by real-time PCR. ................. 139 
Table 3.12 Interpretation of intensity ratio for rAG12b-IgG avidity western 
blot optimization study. .................................................................... 161 
Table 3.13 Summarized optimization result of rAG12b-IgG avidity western 
blot. ................................................................................................... 162 
Table 3.14 rAG12b-IgG avidity western blot results. ........................................ 165 
Table 3.15 Optimization result of rAG12b-IgG avidity ELISA at different 
antigen concentrations and serum dilutions. .................................... 167 
Table 3.16 Optimization result of rAG12b-IgG avidity ELISA using 
Toxoplasma-negative serum samples. .............................................. 167 
Table 3.17 rAG12b-IgG avidity ELISA results.................................................. 170 
 xiii 
 
Table 3.18 Interpretation of intensity ratio for rAG18-IgG avidity western 
blot optimization study. .................................................................... 173 
Table 3.19 Summarized optimization result of rAG18-IgG avidity western 
blot. ................................................................................................... 174 
Table 3.20 rAG18-IgG avidity western blot results ........................................... 177 
Table 3.21 Optimization result of rAG18-IgG avidity ELISA with different 
antigen concentrations and serum dilutions. .................................... 179 
Table 3.22 Optimization result of rAG18-IgG avidity ELISA using 
Toxoplasma- negative serum samples. ............................................. 179 
Table 3.23 rAG18-IgG avidity ELISA results. ................................................... 182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
 
LIST OF FIGURES 
        Page 
Figure 1.1 Microscopic examinations of (A) tachyzoites, (B) bradyzoites 
and (C) oocysts of T. gondii (Hill and Dubey, 2002). .......................... 3 
Figure 1.2 Schematic drawings of a tachyzoite (top left), a bradyzoite (top 
right) and a sporozoite (bottom) of T. gondii (Dubey et al., 
1998). .................................................................................................... 4 
Figure 1.3 Life cycle of T. gondii (Robert-Gangneux and Darde, 2012). ............. 8 
Figure 1.4 The major cytokines involved in cell-mediated immune response 
towards tachyzoites and their relationships (Waree, 2008). ............... 20 
Figure 2.1 Flow chart of the overall methodology of this study, as divided 
into Parts I and II. ............................................................................... 48 
Figure 3.1 IgG-ELISA OD readings of pooled positive serum sample, 
pooled negative serum sample, a LGA serum sample, and a 
HGA serum sample before pre-adsorption (non-preadsorbed), 
after pre-adsorption with E. coli pellet and after pre-adsorption 
with E. coli pellet and lysate............................................................. 104 
Figure 3.2 Representative immunoscreening images of a T. gondii cDNA 
phage clone (A) at 10
1
 dilution (or 1:10) and (B) non-diluted. ........ 106 
Figure 3.3 Primary and secondary antibodies optimizations performed on 
T. gondii cDNA phage clones. Serum dilution at 1:100 and 
secondary antibody dilution at 1:2000 (C) were found to be 
optimum. ........................................................................................... 109 
Figure 3.4 Immunoscreening to determine the non-reactivity and reactivity 
of a T. gondii cDNA phage clone AG12b when screened with 
(A) Group I, and (B) Groups II and III serum samples. ................... 113 
Figure 3.5 Optimization of urea molarity for IgG avidity immunoscreening 
using (A) TBST, (B) TBST-6 M urea and (C) TBST-8 M urea....... 116 
Figure 3.6 IgG avidity immunoscreening of clone AG12b with (A) TBST 
and (B) TBST-6 M urea wash. ......................................................... 119 
Figure 3.7 IgG avidity immunoscreening of clone AG18 with (A) TBST 
and (B) TBST-6 M urea wash. ......................................................... 120 
Figure 3.8 Agarose gel electrophoresis image of plasmids extracted from 
clone AG12b. .................................................................................... 122 
Figure 3.9 DNA sequence alignment of AG12b (1182 bp) and T. gondii 
ME49 apical complex lysine methyltransferase 
 xv 
 
(TGME49_216080) showing 100% identity at nucleotide 
position 770 to 1951 of TGME49_216080. ..................................... 125 
Figure 3.10 Coding region (underlined) of AG12b (630 bp) encode 210 
amino acids of apical complex lysine methyltransferase 
(AKMT) protein. .............................................................................. 125 
Figure 3.11 Agarose gel electrophoresis image of plasmids extracted from 
clone AG18. ...................................................................................... 127 
Figure 3.12 DNA sequence alignment of AG18 (1584 bp) and T. gondii GT1 
FHA-domain containing protein (TGGT1_202840) showing 
100% identity at nucleotide position 1543 to 3126 of 
TGGT1_202840. The 3 nucleotides at position 3127 to 3129 of 
TGGT1_202840 encoded a stop codon. ........................................... 129 
Figure 3.13 Coding region (underlined) of AG18 (1584 bp) encode 528 
amino acids of FHA-domain containing protein. ............................. 131 
Figure 3.14 In-vivo amplification of AG12b-real-time PCR and the melting 
curves. ............................................................................................... 134 
Figure 3.15 In-vitro amplification of AG12b-real-time PCR and the melting 
curves. ............................................................................................... 135 
Figure 3.16 In-vivo amplification of AG18-real-time PCR and the melting 
curves. ............................................................................................... 137 
Figure 3.17 In-vitro amplification of AG18-real-time PCR and the melting 
curves. ............................................................................................... 138 
Figure 3.18 Map of the pET32 expression vector showing the location of the 
AG12b gene embedded in the vector sequence. ............................... 141 
Figure 3.19 Deduced amino acid sequence of AG12b-pET32 construct 
showing the in-frame translation of the AG12b gene with 
thioredoxin (Trx) and Histidine-tag coding sequence. ..................... 142 
Figure 3.20 Map of the pET32 expression vector showing the location of the 
AG18 gene embedded in the vector sequence. ................................. 144 
Figure 3.21 Deduced amino acid sequence of AG18-pET32 construct 
showing the in-frame translation of the AG18 gene with Trx and 
Histidine-tag coding sequence. ......................................................... 146 
Figure 3.22 Expression analysis of rAG12b. ....................................................... 148 
Figure 3.23 Analysis of rAG12b native purification fractions. ........................... 150 
Figure 3.24 SDS-PAGE analysis of rAG12b after buffer-exchanged. ................ 152 
Figure 3.25 Expression analysis of rAG18. ......................................................... 154 
 xvi 
 
Figure 3.26 Analysis of rAG18 denaturing purification fractions. ...................... 156 
Figure 3.27 SDS-PAGE analysis of rAG18 after buffer-exchanged. .................. 158 
Figure 3.28 Optimization study of rAG12b-IgG avidity western blot at 
different protein concentration (A) 4 µg/ml and (B) 8 µg/ml 
using 3 different washing buffers. .................................................... 160 
Figure 3.29 Representative images of rAG12b-IgG avidity western blot. .......... 164 
Figure 3.30 Avidity index (AI) of LGA and HGA serum groups obtained 
from rAG12b-IgG avidity ELISA when treated with PBST-4 M 
urea, PBST-6 M urea, and PBST-8 M urea. PBST-8 M urea 
showed non-overlapping AI ranges for the two serum groups......... 168 
Figure 3.31 Avidity index (AI) scores of 44 serum samples tested with 
rAG12b-IgG avidity ELISA. ............................................................ 170 
Figure 3.32 Optimization study of rAG18-IgG avidity western blot at 
different protein concentration (A) 2.5 µg/ml and (B) 5 µg/ml 
using 3 different washing buffers. .................................................... 172 
Figure 3.33 Representative images of rAG18-IgG avidity western blot. ............ 176 
Figure 3.34 Avidity index (AI) of LGA and HGA serum groups obtained 
from rAG18-IgG avidity ELISA when treated with PBST-4 M 
urea, PBST-6 M urea, and PBST-8 M urea. PBST-8 M urea 
showed non-overlapping AI ranges for the two serum groups......... 180 
Figure 3.35 Avidity index (AI) scores of 44 serum samples tested with 
rAG18 protein. .................................................................................. 182 
 
 
  
 xvii 
 
LIST OF ABBREVIATIONS  
  
ABTS     2, 2'-azino-bis 3-ethylbenzthiazoline-6- sulfonic acid 
APS     ammonium persulphate  
BLAST    Basic Local Alignment Search Tool 
bp    base pair  
BSA    bovine serum albumin 
cDNA    complementary DNA  
DALY    disability-adjusted life year 
DMSO    dimethyl sulfoxide 
DNA     deoxyribonucleic acid  
E. coli     Escherichia coli  
ELISA    enzyme-linked immunosorbent assay  
EtBr    ethidium bromide  
His    histidine 
HRP     Horseradish Peroxidase 
i.e.     id est (that is)  
Ig    Immunoglobulin  
INFORMM   Institute for Research in Molecular Medicine 
IPTG    Isopropyl-beta-D-thiogalactopyranoside 
IVIAT    in-vivo induced antigen technology  
Kb    kilo base pair 
kDa    kilo Dalton  
LB     Luria-Bertani 
MALDI-TOF/TOF  Matrix-Assisted Laser Desorption/ Ionization-Time of  
Flight/ Time of Flight  
MWCO   molecular weight cut-off 
NCC     nitrocellulose membrane circle  
NCP    nitrocellulose membrane 
Ni-NTA   nickel-nitrilotriacetic acid  
OD     optical density 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
RC DC
TM
    reducing agent and detergent compatible  
RNA     ribonucleic acid 
SDS    sodium dodecyl sulfate 
SDS-PAGE   sodium dodecyl sulphate polyacrylamide gel  
electrophoresis  
TB     terrific broth  
TBE    Tris/ Borate/ EDTA  
TBS    Tris buffered saline  
TEMED   tetramethylethylenediamine   
T. gondii    Toxoplasma gondii 
UV     ultraviolet  
 
 
  
 xviii 
 
PENGENALPASTIAN KLON FAJ cDNA Toxoplasma gondii YANG 
BERPOTENSI DAN PENGHASILAN PROTEIN REKOMBINAN BAGI 
PEMBANGUNAN ASAI IgG AVIDITI UNTUK SERODIAGNOSIS 
PENYAKIT TOKSOPLASMOSIS  
 
ABSTRAK 
Toksoplasmosis merupakan jangkitan berleluasa di seluruh dunia yang 
disebabkan oleh Toxoplasma gondii. Jangkitan akut (primer) di dalam kalangan 
wanita hamil boleh menyebabkan toksoplasmosis kongenital yang mengakibatkan 
kecacatan neonatal, kerosakan saraf dan mata fetus, atau kematian janin. Oleh sebab 
itu, penilaian peringkat toksoplasmosis (kronik atau akut) di dalam kalangan wanita 
hamil adalah penting untuk pengurusan pesakit yang baik. Ujian serologi kekal 
sebagai pendekatan yang paling biasa untuk diagnosis makmal dan juga penilaian 
peringkat jangkitan bagi penyakit Toxoplasma. Pengunaan kaedah IgG aviditi telah 
dibuktikan berguna dalam perbezaan jangkitan toksoplasmosis akut dan kronik. 
Aviditi IgG adalah rendah pada awal jangkitan dan meningkat secara beransur-ansur 
dari masa ke masa. Aviditi IgG yang tinggi mengesahkan jangkitan kronik, manakala 
aviditi IgG yang rendah menunjukkan kemungkinan jangkitan yang baru. 
Kebanyakan asai serologi Toxoplasma di pasaran adalah berdasarkan ekstrak asli 
antigen yang berasas T. gondii yang dikultur secara in-vivo atau in-vitro, dan asai-
asai ini menunjukkan keputusan yang bervariasi. Antigen T. gondii yang dihasikan 
secara rekombinan merupakan alternatif yang menarik dalam pembangunan asai IgG 
aviditi yang lebih baik. Oleh itu, kajian ini dijalankan untuk memenuhi keperluan 
tersebut. Dalam kajian ini, 30 klon faj cDNA T. gondii telah diuji dengan 
imunosaringan menggunakan sampel serum yang negatif terhadap Toxoplasma-
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khusus IgG dan IgM (IgG-, IgM-) dan keputusan ujian ini telah menunjukkan 
sembilan klon adalah ≥ 70% tidak-kereaktifan. Klon-klon ini telah diuji seterusnya 
dengan sampel serum yang positif terhadap Toxoplasma-khusus IgG dan IgM (IgG+, 
IgM+) dan tujuh klon dengan ≥ 70% kereaktifan didapati. Selanjutnya, klon-klon ini 
diuji dengan imunosaringan IgG aviditi menggunakan sampel serum yang IgG aviditi 
rendah (LGA) dan IgG avidity tinggi (HGA). Dua klon cDNA yang menunjukkan 
prestasi tertinggi telah dikenal pasti dan dijujuk. Klon AG12b mengekodkan protein 
T. gondii apical complex lysine methyltransferase (AKMT) manakala klon AG18 
mengekodkan T. gondii forkhead-associated (FHA) domain-containing protein. 
Jujukan sisipan DNA telah diklonkan ke dalam vektor ekspresi pET32. Protein 
rekombinan gabungan-His telah diekspres dan dinilai dengan blot western dan 
ELISA IgG aviditi. Dengan blot western IgG aviditi, rAG12b mengenal pasti 86.4% 
sampel serum LGA (n=22) dan 90.9% HGA (n=22); manakala rAG18 mengenal 
pasti 81.8% sampel serum dari setiap kumpulan LGA and HGA. Dengan ELISA IgG 
aviditi, rAG12b mengenal pasti 86.4% sampel serum dari setiap kumpulan LGA 
(n=22) and HGA (n=22); manakala rAG18 mengenal pasti 77.3% sampel serum 
LGA dan 86.4% HGA. Secara umum, keputusan yang ditunjukkan adalah lebih baik 
atau setanding dengan asai IgG avidity lain yang dilaporkan. Secara kesimpulan, 
kajian ini telah mengenalpastikan dua klon faj cDNA T. gondii dengan potensi 
diagnostik untuk diguna dalam asai IgG aviditi dan berjaya mengekspreskan dan 
menulenkan protein rekombinan yang berkenaan sebagai rAG12b dan rAG18. Nilai 
diagnostik tinggi terutamanya oleh rAG12b, membuat kedua-dua protein rekombinan 
ini berpotensi untuk diguna dalam pembangunan asai IgG aviditi Toxoplasma untuk 
serodiagnosis penyakit toksoplasmosis.   
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IDENTIFICATION OF POTENTIAL Toxoplasma gondii cDNA PHAGE 
CLONES AND PRODUCTION OF THE CORRESPONDING 
RECOMBINANT PROTEINS IN THE DEVELOPMENT OF IgG AVIDITY 
ASSAY FOR SERODIAGNOSIS OF TOXOPLASMOSIS 
 
ABSTRACT 
Toxoplasmosis is a worldwide infection caused by Toxoplasma gondii. Acute 
(primary) infection in pregnant women can lead to congenital toxoplasmosis which 
causes neonatal malformation, neurological damage, eye lesions or fetal death. 
Therefore, assessment of the stage (chronic or acute) of toxoplasmosis in pregnant 
women is crucial for appropriate patient management. Serodiagnosis remains the 
most common approach for laboratory diagnosis of Toxoplasma infection as well as 
to assess the stage of the infection. Determination of IgG avidity has been proven to 
be useful in differentiating acute from chronic Toxoplasma infection. The IgG 
avidity is low at the beginning of the infection and gradually increases over time. 
High IgG avidity confirms chronic infection while low IgG avidity indicates a 
probable recent infection. Most of the commercially available Toxoplasma 
serological assays uses native antigen isolated from in-vivo or in-vitro culture of T. 
gondii, and they show variability in performance. The recombinantly produced T. 
gondii antigens are attractive alternatives in the development of an improved IgG 
avidity assay. Therefore, the present study was conducted to address this need. In this 
study, 30 T. gondii cDNA phage clones were immunoscreened using serum samples 
negative for Toxoplasma-specific IgG and IgM (IgG-, IgM-), and the results showed 
9 clones with non-reactivity of ≥ 70%. These clones were then tested with serum 
samples positive for Toxoplasma-specific IgG and IgM (IgG+, IgM+) and showed 7 
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clones with the reactivity of ≥ 70%. They were further tested with IgG avidity 
immunoscreening using low IgG avidity (LGA) and high IgG avidity (HGA) serum 
samples. Two cDNA clones with the highest performance were identified and 
sequenced. Clone AG12b encoded T. gondii apical complex lysine methyltransferase 
(AKMT) protein while AG18 encoded T. gondii forkhead-associated (FHA) domain-
containing protein. The DNA sequences were cloned into pET32 expression vector; 
and the His-tagged recombinant proteins rAG12b and rAG18 were expressed and 
evaluated with IgG avidity western blot and ELISA. With IgG avidity western blot, 
rAG12b identified 86.4% LGA (n=22) and 90.9% HGA serum samples (n=22); 
while rAG18 identified 81.8% of each LGA and HGA serum group. With IgG 
avidity ELISA, rAG12b identified 86.4% of each LGA (n=22) and HGA (n=22) 
serum group; while rAG18 identified 77.3% LGA and 86.4% HGA serum samples. 
In general, these results were either better or comparable to the reported IgG avidity 
assays. In conclusion, this study has identified two T. gondii cDNA phage clones 
with diagnostic potential for use in IgG avidity assay and successfully expressed and 
purified the corresponding recombinant proteins as rAG12b and rAG18. The good 
diagnostic potential demonstrated by the recombinant proteins, in particular, 
rAG12b, make them potentially useful in the development Toxoplasma IgG avidity 
assay for serodiagnosis of toxoplasmosis.  
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CHAPTER 1 
INTRODUCTION 
 
1.1  Toxoplasma gondii and toxoplasmosis 
Toxoplasma gondii (T. gondii) is an obligate intracellular protozoan parasite 
that causes over 6 billion cases of human infection worldwide (Furtado et al., 2011). 
The high prevalence of this infection makes it one of the most common parasitic 
infections in human. T. gondii can infect and grow in many cell types of various 
animal species, which covers all warm-blooded animals including human 
(Schwartzman, 2001). The definitive host of this parasite is Felidae members 
including domestic cats. T. gondii infection, or toxoplasmosis, is commonly 
asymptomatic or shows only mild symptoms in immunocompetent adults. However, 
it can cause severe clinical symptoms in immunocompromised persons or 
congenitally infected infants.  
Toxoplasmosis in human is generally categorized into acquired 
toxoplasmosis, congenital toxoplasmosis, and reactivated toxoplasmosis. Acquired 
toxoplasmosis may be transmitted through T. gondii oocysts, usually by direct 
transmission, or ingestion of tissue cysts found in the intermediate host. Organ 
transplantation from a Toxoplasma-positive donor may also contribute to this. 
Congenital toxoplasmosis occurs when a pregnant woman gets primary T. gondii 
infection during her pregnancy and vertically transmitted the infection to her fetus. 
The frequency of the cross-placenta transmission increases with the gestational age 
but the risk for severe clinical symptoms in the infant is higher if the congenital 
infection occurs at the early pregnancy stage. Congenital toxoplasmosis may result in 
fetal death, miscarriage and various debilitating effects in the infected children. On 
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the other hand, reactivated toxoplasmosis occurs in an immunocompromised person 
when a chronically infected person becomes immunosuppression, and this condition 
can be life-threatening.  
 
1.2  Taxonomy of T. gondii  
T. gondii is classified in domain Eukarya as it is a single cell organism that 
contains a nucleus and has membrane-bound organelles. It is a member of Kingdom 
Alveolata, which is one major group of Protists. This organism is categorized under 
Phylum Apicomplexa and Class Coccidia, where all members of this group are 
obligate intracellular parasites that must live and reproduce within an animal cell. 
The parasite is a member of Order Eucoccidiorida, Family Sarcocystidae, and Genus 
Toxoplasma since it carries out life cycle in more than one host while the definitive 
host is a member of Felidae. Toxoplasma gondii is the sole member of the genus 
Toxoplasma.  
 
1.3  Stages and morphology of T. gondii 
T. gondii has three distinct infectious stages, i.e. the tachyzoite, bradyzoite, 
and sporozoite. The microscopic examinations and the schematic drawings of the 
three different forms of T. gondii are shown in Figures 1.1 and 1.2, respectively.  
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(A) Crescent-shaped (arrows) and dividing (arrowhead) tachyzoites observed in 
impression smear of lung.  
 
(B) Tissue cysts found in muscle (left) and brain (right). Tissue cyst wall is thin 
(arrows) and it contains hundreds of bradyzoites (arrowheads).   
 
(C) Unsporulated (left) and sporulated (right) oocysts with oocysts wall (big arrows) 
enclosing two sporocysts (arrowheads) and sporozoites (small arrow).  
Figure 1.1 Microscopic examinations of (A) tachyzoites, (B) bradyzoites and (C) 
oocysts of T. gondii (Hill and Dubey, 2002). 
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Figure 1.2 Schematic drawings of a tachyzoite (top left), a bradyzoite (top right) 
and a sporozoite (bottom) of T. gondii (Dubey et al., 1998).   
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1.3.1 Tachyzoite 
T. gondii tachyzoite is the rapidly multiplying form of the parasite which is 
also known as the trophozoite, the proliferative form, the feeding form, and 
endozoite (Dubey, 2008). Nicolle and Manceaux in the year 1909 found this form of 
the parasite from the tissue of the gundii rodent. It is oval or crescent-shaped with a 
conoidal anterior end and a rounded posterior end (Figure 1.1A) with approximately 
2-4 µm of width and 6-8 µm of length. The tachyzoite contains various organelles 
and inclusion bodies (Frenkel, 1973). A few structural and secretory elements are 
located within the anterior region of the tachyzoite, including apical ring, polar ring, 
conoid and inner membrane complex (Figure 1.2), these make up the apical complex 
that is responsible for the mobility and host invasion of the parasite. Apicoplast, an 
organelle that is typical for the members of Apicomplexa, is also present in the 
tachyzoite (Figure 1.2). This is a non-photosynthetic organelle homologous to the 
chloroplast in the plant that is responsible for protein synthesis and may be involved 
in fatty acid synthesis and lipid metabolism (Lim and McFadden, 2010).  
T. gondii tachyzoites invade all types of cells and the invasion process is by 
active penetration mediated by proteins secreted from the microneme, rhoptries, and 
dense granules (Arrizabalaga and Boothroyd, 2004; Boothroyd and Dubremetz, 2008; 
Besteiro et al., 2011). The tachyzoites multiply asexually within the host cell by a 
process called endodyogeny (Goldman et al., 1958), in which two daughter cells are 
formed within the parent parasite. During the asexual stage, the T. gondii tachyzoite 
grows rapidly intracellular.   
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1.3.2 Bradyzoite 
Bradyzoite (brady in Greek = slow) was proposed by Frenkel in the year 1973 
to describe the stage of T. gondii where it replicates slowly within a host cell and 
surrounded by a thin, elastic wall (Figure 1.1B) to form cysts in tissues. Encysted 
bradyzoites vary in size, are less susceptible to destruction by proteolytic enzymes 
and are found mostly in neural and muscular tissues including the brain, eye, skeletal, 
cardiac muscle and the central nervous system. The tissue cysts site may vary 
depending on the host species (Ferguson and Dubremetz, 2007). Encysted 
bradyzoites do not cause inflammation and thus have little effect on the surrounding 
cellular function and host immune response. However, the bradyzoites released from 
a breakdown cysts can be converted to the active tachyzoites causing necrosis and 
inflammation or acute encephalitis in the immunocompromised patient 
(Schwartzman, 2001; Dubey, 2007). The internal structure of bradyzoite is similar to 
tachyzoite with the most distinct difference is the position of the nucleus. The 
nucleus in bradyzoite is located towards the posterior end while the nucleus in 
tachyzoite is more centrally located (Figure 1.2).  
 
1.3.3 Sporozoite 
Oocysts formation takes place in the small intestine of a definitive host 
(usually a cat) after the fertilization of T. gondii female gametes by the male gametes. 
The non-infective parasite oocysts are then released into the intestinal lumen after the 
rupture of the intestinal epithelial cells. These oocysts are resistant to the 
environment and sporulate under the appropriate environmental condition, i.e. good 
aeration, humidity, and temperature. Each sporulated oocysts contain two sporocysts 
which later divided into four sporozoites (Figure 1.1C). The sporulated oocysts are 
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infectious (Dubey and Frenkel, 1972). The ultrastructure of sporozoite is similar to 
that of tachyzoite, except that there is abundance of micronemes, rhoptries, and 
amylopectin granules in the former (Figure 1.2).   
Unlike the other two forms of T. gondii, sporozoite can contaminate the water 
source as it survives in water (Dubey, 2007). Sporulated oocysts are infectious in 
water with a temperature between 10
o
C to 20
o
C, but the infectivity decreases 
dramatically above 30
o
C, and are killed at 60
o
C (Dubey, 1998b). A toxoplasmosis 
outbreak in Brazil in November 2001 to January 2002 infecting 155 persons was 
caused by T. gondii oocysts that contaminated the reservoir (de Moura et al., 2006).  
 
1.4  Life cycle of T. gondii 
The complete T. gondii life cycle was resolved by Dubey and Frenkel (1972) 
through the description of the asexual and sexual phases of T. gondii that takes place 
in the small intestine of a cat. The sexual cycle occurs in the definitive hosts (the 
Felidae family) while the asexual cycle occurs in the intermediate hosts (all warm-
blooded mammals) (Figure 1.3).   
A cat gets infected by T. gondii either by ingestion of tachyzoites, encysted 
bradyzoites, and sporozoites of the parasite (Dubey, 2001; Dubey, 2006). It has been 
reported that the T. gondii is transmitted most efficiently by bradyzoites to the cat 
and by the oocysts to other hosts. As such, cats may shed millions of oocysts after 
ingestion of a bradyzoite while mice may not get infected even after ingestion of 100 
bradyzoites. Meanwhile, pigs and mice can be infected by ingestion of single oocyst 
although cat may only get infected after ingestion of more than 100 oocysts (Dubey, 
2008).  
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Figure 1.3 Life cycle of T. gondii (Robert-Gangneux and Darde, 2012).  
The sexual cycle takes place in the definitive hosts while asexual cycle occurs in 
intermediate hosts.  
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Upon ingestion of encysted bradyzoites, the cyst wall of the bradyzoite is 
dissolved by proteolytic enzymes in the cat’s intestine and stomach. The bradyzoites 
are then release and penetrate the epithelial cells of the small intestine. This is 
followed by multiplication of the bradyzoites asexually in the epithelial cells, 
forming a stage known as schizonts. Schizonts produce merozoites and the 
merozoites form male and female gametes through gametogonia. The male gamete 
uses its flagella to reach the female gamete and fertilizes the female gamete. The 
oocyst wall is then formed, in the epithelium cells of the small intestine of the cat.  
Oocysts are released into the intestinal lumen following the rupture of the 
intestinal cells, usually 3-10 days after the cat consumes the bradyzoites. If the cat 
ingests oocysts or tachyzoites, the prepatent period is 18 days or more (Dubey, 2001; 
Dubey, 2006). The oocysts are passed into the feces of the cat and get disseminated 
to the environment through the feces. Several millions of the unsporulated oocysts 
may be released in the feces of an infected cat. Since the sexual cycle of T. gondii 
occurs solely in the definitive host, only felids shed the oocysts of T. gondii (Miller 
et al., 1972). The excreted oocysts get sporulated under suitable environment 
condition within 1-5 days and then infect its hosts, e.g. cow, sheep or human, through 
contaminated water or soil.  
Human and other intermediate hosts may accidentally ingest infectious T. 
gondii sporulated oocysts, which initiate the asexual stage of T. gondii. Once 
ingested, the sporozoites escape from the oocysts and invade the epithelial cells 
lining the internal surfaces of the small intestine. The sporozoites multiply asexually 
to form tachyzoites which invaded other host cells by active penetration. Inside the 
host cells, the tachyzoites form vacuoles surrounding them to protect themselves 
from host immune system and then multiply asexually within the host cells. Two 
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daughter cells are formed within the parent parasite, which then replace the parent 
parasite. The process is repeated continuously until the host cell is filled with the 
parasites (usually 8-32 tachyzoites in a host cell) that leads to host cell death and 
subsequently breakdown of the cell. The tachyzoites are then released into the blood 
stream and disseminated in the body. The same invasion and replication processes 
are initiated in a new host cell. The multiplication and accumulation of the 
tachyzoites in the host cause acute Toxoplasma infection. The infection of circulating 
monocytes is thought to be the medium of spreading the infection to other tissues 
(Dubey, 1998a; Schwartzman, 2001).  
Meanwhile, the large number of the tachyzoites found in the host cells also 
triggers the activation of body’s immune system. Following this, the tachyzoites 
transform into slower multiplying form known as bradyzoites and establish chronic 
infection. Bradyzoites accumulate in large number within a host cell and are 
surrounded by a thin wall to form a tissue cyst. A tissue cyst can have hundreds of 
bradyzoites within the enclosed area.  
 
1.5  Epidemiology  
Toxoplasmosis is a widespread infection in animals and humans worldwide. 
It is estimated that one-third of the world’s human population have this infection 
(Montoya and Liesenfeld, 2004). Prevalence studies of this infection have shown 
variable results from country to country and place to place, ranging from 10 – 80%. 
Many factors determine the seroprevalence of T. gondii. Higher seroprevalence is 
often seen in tropical countries with humid and warm climates which encourage the 
sporulation of T. gondii oocysts. Dietary habit of human is also a factor that affects 
the seroprevalence since a person can get infected through ingestion of T. gondii 
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bradyzoites in non-properly cooked meat. Economic, social or cultural habits 
including water quality, sanitation level, and education also play a role. 
Seroprevalence is often categorized into low, moderate and high where low indicate 
seroprevalence of below 30%, moderate indicate seroprevalence of 30-50% and high 
indicate the seroprevalence above 50%. In general, low seroprevalences were 
observed in North America, South East Asia, Northern Europe, and in Sahelian 
countries of Africa. Meanwhile, moderate seroprevalences were observed in Central 
and Southern Europe, and high prevalences were observed in Latin America and 
tropical African countries (Robert-Gangneux and Darde, 2012).  
 In the United States, T. gondii seroprevalence has decreased over the years. 
The seroprevalence among people born in the United States of age 12-49 was 
reported to decrease from 14% in 1988-1994 to 9% in 1999-2004, and 6.7% in the 
year 2009-2010 by using samples from the population-based National Health and 
Nutrition Examination Survey (NHANES). The women borned in USA of age 15-44 
were reported to have a prevalence of 11% in the year 1999-2004 and the number 
decreased to 9.1% in 2009-2010 (Smith et al., 1996; Jones et al., 2007; Jones et al., 
2014). Besides, the seroprevalence among military recruits at the year 1962 and 1989 
showed seroprevalence of 14.4% and 9.5%, respectively, clearly indicating a 
decreasing trend (Smith et al., 1996).  
In Colombia, a national study in the year 1980 found an overall 47% of T. 
gondii seroprevalence with similar proportions in men and women. The 
seroprevalence among pregnant women in this South America country ranged from 
47% to 73%, throughout 1992 – 2007 (Canon-Franco et al., 2014). Another study in 
the year 2008 found 53% seroprevalence among healthy individuals (Pordeus et al., 
2008).  
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A study in Poland showed mean seroprevalence of 41.3% among 4916 
pregnant women aged 19 – 46 years old from year 1998 to 2003 (Nowakowska et al., 
2006). In another study, the mean prevalence of T. gondii was reported to be 40.6% 
among 8281 Polish pregnant women aged 18 – 47 years old between the years 2004 
and 2012 (Nowakowska et al., 2014). The prevalence obtained in the year 2004 – 
2012 was similar but slightly lower compared to the prevalence obtained in the year 
1998 – 2003, showing a consistent rate of T. gondii infection in the Poland.    
The mean T. gondii seroprevalence reported among general Mexican 
population is 50%. Since Mexico is a large country which covers areas of subtropical, 
arid and temperate regions, the prevalence varies depending on the climate and 
humidity of the area (Galvan-Ramirez et al., 2012). High prevalence was reported in 
wet coastal regions of the Gulf while arid regions have low prevalence (Hernandez-
Cortazar et al., 2015).  
Brazil has a very high T. gondii seroprevalence. It is estimated that 50-80% of 
women of childbearing age and 50% of children at school age are infected by T. 
gondii (Dubey et al., 2012). A survey conducted in the year 1964 using serum 
samples collected from males age 18-21 reported T. gondii seroprevalence of 56% in 
samples from Brazil compared with 13% in the United States (Walls and Kagan, 
1967; Walls et al., 1967; Lamb and Feldman, 1968). Santos et al. (2009) showed 
97.4% T. gondii seroprevalence among 116 farm workers in Brazil. Another study in 
the year 2008 found 67.7% T. gondii prevalence among pregnant women who were 
screened for toxoplasmosis in Goiania, Brazil (Sartori et al., 2011).  
In Malaysia, seroprevalence of T. gondii has shown an increasing trend 
among healthy individuals and pregnant women. The prevalence in healthy 
individuals was reported as 13.9 – 20% in 1971-1980, and increased to 25 – 30% in 
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1981-1990. Meanwhile, the prevalence among pregnant women was reported as 23 – 
27.4 %  in the year 1971-1980, 27.9 – 31.6% in the year 1991-2000, and 49% in the 
year of 2003 (Nissapatorn et al., 2003; Nissapatorn and Abdullah, 2004). A recent 
study found 42.3% T. gondii seroprevalence among pregnant women in Malaysia 
(Andiappan et al., 2014).  
  
1.6  Transmission   
Toxoplasmosis is transmitted to humans in three main ways: congenital, 
foodborne and animal-to-human (zoonotic). Organ transplantation and blood 
transfusion also transmit the infection although these are uncommon.  
 
1.6.1 Congenital  
In a recent study, the global annual incidence of congenital toxoplasmosis 
was estimated to be 190,100 cases, which were approximately 1.5 cases per 1000 
livebirths (Torgerson and Mastroiacovo, 2013). A pregnant woman who acquires 
primary T. gondii infection during her pregnancy may vertically transmit the 
infection to the fetus through the infected placenta (Montoya and Liesenfeld, 2004). 
The maternal-fetal transmission rate is approximately 10% during the first trimester, 
30% during the second trimester and 60 to 70% during the third trimester. Therefore, 
the risk of congenital infection increases from 6% at 13th week to 72% at the 36th 
week of gestation (Dunn et al., 1999). However, the risk of congenital infection and 
the risk of developing clinical signs are inversely related. The risk of developing 
clinical signs has been estimated to be 61% at 13th week and dropped to 25% at 26th 
week followed with 9% at 36th week of gestation (Dunn et al., 1999). A fetus who is 
congenitally infected at early gestational age usually suffers severe or life-
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threatening consequences compared with those infected during late pregnancy. The 
latter often has mild clinical symptoms or sometimes asymptomatic. A pregnant 
woman who acquires primary infection between the 10th to 24th week of gestational 
age tends to have a child with high probability of severe clinical symptoms (Tenter et 
al., 2000).  
On the other hand, pregnant women with chronic T. gondii infection have 
little risk or no risk of transmitting the infection to their fetus. Nevertheless, 
chronically infected women who are immunosuppressed may transmit the infection 
to the fetus. 
 
1.6.2 Foodborne 
Weinman and Chandler (1954) suggested that the toxoplasmosis may be 
transmitted by ingestion of raw or undercooked meat. This was then supported by 
Jacobs et al. (1960) when they reported that the bradyzoites were resistant to 
proteolytic enzymes. In another study, Desmonts et al. (1965) found that the yearly 
acquisition rates of T. gondii infection rose from 10% to 50% or 100% when 
different barely cooked meats were added to the orphans’ daily diets.  
In a multicenter European study, ingestion of inadequately cooked meat 
among pregnant women was identified as the main risk for toxoplasmosis (Cook et 
al., 2000). Pomares et al. (2011) reported that toxoplasmosis caused by atypical T. 
gondii strains in France were most probably acquired via ingestion of raw horse meat 
originated from Canada and Brazil.    
On the other hand, the T. gondii oocysts which survive in water may 
contaminate soil and water sources. Drinking untreated water or unpasteurized milk 
was thought to increase the risk of toxoplasmosis transmission (Jones et al., 2009). 
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Oocysts in the soil can mechanically spread by invertebrates such as flies, 
cockroaches, earthworms into other forms of food source. Therefore, inadequate 
washing of contaminated raw vegetables and fruits may result in T. gondii infection.  
Consumption of raw oysters, mussels and clams may be a potential risk for 
toxoplasmosis (Jones et al., 2009). The T. gondii oocysts are carried to the ocean by 
contaminated water sources and infect the wild oysters (Lindsay et al., 2004).  
In the United Sates, toxoplasmosis has been identified as the second leading 
cause of foodborne illness-related death with an estimated of 327 deaths, and fourth 
leading cause of foodborne illness-related hospitalizations with 4428 hospitalizations 
annually (Scallan et al., 2011). In Greece, toxoplasmosis is ranked the top 5 
contributors of foodborne illnesses, causing an estimated 9.7 years of live lost, 14 
years lived with disability and disability-adjusted life year (DALY) of 23 years per 
million persons (Gkogka et al., 2011).    
 
1.6.3 Animal-to-human (zoonotic)  
Human contact with cat fecal material containing T. gondii oocysts is one of 
the risk factors of animal-to-human transmission. Domestic cats are the main source 
of this transmission route as a cat may excrete millions of oocysts after ingestion of 
only one bradyzoite. The domestic cats or kittens may get infected by ingesting 
intermediate hosts such as rodents and birds; then they contaminate the environment 
with T. gondii oocysts shed in their feces. Sporulated oocysts are resistant to 
environment conditions up to 18 months at temperatures of -20
o
C to 35
o
C (Frenkel et 
al., 1975). Improper handling of cat feces may cause the transmission to the cat 
owner. A study in Canada screened T. gondii antibody from 998 children and 
adolescents reported the infection chance of the rural children with more than one cat 
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were two times higher than those who had one cat; and three times higher than 
children with no cat (Pereira et al., 1992). Similarly, Jones et al. (2009) found that 
there is an increased in T. gondii transmission risks with cat owners who had three or 
more kittens. Infected wild felids in zoos may transmit the infection to zoo workers 
and visitors through the shed oocysts. It was found that 83% of 131 bobcats, one of 
the main wild felids in the United States, were seropositive to T. gondii (Mucker et 
al., 2006). 
 
1.6.4 Others  
Solid organ transplantation (SOT) is a potential transmission route of T. 
gondii infection. Toxoplasma-seronegative recipient gets infected by T. gondii after 
receiving the transplanted organ from a Toxoplasma-seropositive donor. This 
transmission was found mainly in cases of heart transplantation as cardiac muscle is 
one of the common sites for encysted bradyzoites. Approximately 50% of 
seronegative heart transplantation recipients acquired toxoplasmosis from the 
seropositive donors when prophylactic medication was not given (Schaffner, 2001). 
The rates of transmission were reported as 20% and less than 1% for liver and kidney 
transplantations respectively (Schaffner, 2001).  
 The risk of T. gondii transmission through blood transfusion is extremely low. 
Serological testing of T. gondii antibodies in the blood of donors is unnecessary 
except for those that are to be delivered to immunocompromised individuals and 
pregnant women. These high-risk groups are advised to receive blood component 
without T. gondii antibody (Singh and Sehgal, 2010).    
 
 17 
 
1.7  Pathogenesis of toxoplasmosis  
Tachyzoites can invade and multiply in the nucleated cells of all warm-
blooded animals. The sequential release of parasite proteins from three major 
secretory organelles, i.e. the micronemes, rhoptries and dense granules, facilitate host 
cell attachment, invasion, and generation of the parasitophorous vacuoles (Carruthers 
and Sibley, 1997; Coppens and Joiner, 2001). The microneme proteins assist in 
recognition and adhesion to the target host cell while the rhoptry proteins are 
secreted at the time of invasion to produce parasitophorous vacuoles. Dense granules 
secrete enzymes for maturation of the vacuole. The parasitophorous vacuole formed 
inside the host cell is resistant to acidification and lysosomal fusion thus this allow 
the tachyzoites to multiply (Mordue et al., 1999). Extracellular tachyzoites are 
susceptible to environmental changes and likely to be killed by the antibodies.  
The proliferation of tachyzoites intracellularly during acute toxoplasmosis 
causes host cells death. This results in necrosis with a vigorous acute inflammatory 
reaction. As the tachyzoites continue to replicate and burst more host cells, more 
lymphocytic infiltrations develop. Tissue necrosis or lesions may be found in many 
organs including intestines, liver, spleen, pancreas, lung and heart (Dubey, 1996). 
This is damaging to tissues in which the cells do not regenerate, such as brain, eye, 
and muscles (Frenkel, 1974).  
A study by Waree et al. (2007) reported that the inflammatory lesions were 
observed mainly in the liver and spleen following acute toxoplasmosis in mice. The 
accumulation of tachyzoites in the cytoplasm of hepatocytes caused degeneration of 
host cells. As such, the liver appeared swollen with random pinpoint white foci 
caused by hepatocellular necrosis and mononuclear cell infiltration. Meanwhile, the 
spleen was swollen with pale yellow necrotic foci distributed all over the organ. 
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Besides, the brain was congested with microscopic hemorrhages and the 
mononuclear cells that invaded into the meninges also caused meningitis. Lesions in 
central nervous system indicate the process of brain tissue destruction (Waree, 2008).  
The replication of tachyzoites falls under control with the trigger of host 
immune response. Tachyzoites disappear from the visceral tissue and tissue cysts 
containing bradyzoites are formed in neural and muscular tissues (Waree, 2008). 
Tissues are restored while the tissue cysts may appear silent to the host immune 
response and persist for the life of the host.  In chronic toxoplasmosis, lesions are 
often observed in eye muscle and brain rather than in visceral tissues (Dubey and 
Beattie, 1988).  
 
1.8  Immune response  
T. gondii infection triggers both cellular and humoral immune responses in 
the immunocompetent host. The cell-mediated immune response is the main control 
factor for the infection compared to the effects of antibody (Schwartzman, 2001). 
Macrophages produce immunologic mediators which help in the regulation of 
cellular immune response with interleukin-12 (IL-12) as the main activator. IL-12 
activates natural killer (NK) cells and T-cells to produce interferon-γ (IFN-γ). 
Macrophages act synergistically with IFN-γ and tumor necrotic factor (TNF) to kill 
the tachyzoites. The IFN-γ and TNF elevated the free radical and nitric oxide levels 
that also accelerate the killing of the parasite.     
T-lymphocytes with CD8+ are the major effector cells that act against T. 
gondii with the help of T-lymphocytes with CD4+ (Figure 1.4). Mature CD4+ T-
lymphocytes cells are divided into T-helper 1 (Th-1) and 2 (Th-2). CD8+ cells 
secreted IFN-γ while Th-1 CD4+ cells produced IFN-γ and IL-2. IL-2 induce 
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lymphokine to activate natural killer (NK) cells that are cytotoxic to T. gondii-
infected host cells. Th-2 CD4+ cells produce IL-4, IL-5, and IL-10 which play a role 
in down-regulation of the protective cell-mediated immune response. The 
interleukins are able to cross-regulate each other’s activity; IL-10 inhibits production 
of IFN-γ while IFN-γ inhibits multiplication of Th-2 cells. Cytokines produced by T-
lymphocyte cells such as IL-18, IL-17 and IL-15 encourage the production of IFN-γ 
which plays a role during acute and chronic infection (Bhopale, 2003; Waree, 2008).      
The antibodies in humoral immune response are thought to play a minor role 
in killing of T. gondii compared to cell-mediated response. The IgG, IgM, IgA and 
IgE antibodies are produced against the membrane antigens and the other proteins 
excreted by T. gondii. In the presence of complement, specific antibodies act against 
extracellular tachyzoite and lyse it. The specific IgA antibody plays a role in the 
disruption of parasite interaction with the host cells at the mucous membrane. 
Platelets are cytotoxic to tachyzoites in the absence of antibody. The level of 
thromboxane and other metabolites of arachidonic acid also increase simultaneously 
(Bhopale, 2003).  
The immune responses from an immunocompetent individual often control 
the infection effectively, leaving little organ damage. The encysted bradyzoite caused 
little immune response and live long. The bradyzoite can be reactivated to become 
tachyzoites when there are changes in the host immune function and this may cause 
severe tissue and organ damage.   
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Figure 1.4 The major cytokines involved in cell-mediated immune response 
towards tachyzoites and their relationships (Waree, 2008).   
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1.9  Clinical presentations of toxoplasmosis  
T. gondii infection causes variable clinical manifestations based on the 
immune status of the infected person. Acquired toxoplasmosis usually causes mild 
symptoms or is asymptomatic in an immunocompetent individual. However, 
congenital toxoplasmosis may cause debilitating effects in infected infants while 
reactivated toxoplasmosis that occurs in immunocompromised person can be life-
threatening.   
 
1.9.1 Immunocompetent individuals  
Most cases of acquired toxoplasmosis in immunocompetent individuals are 
without clinical symptoms and are self-limited. It is reported that more than 80% of  
infected immunocompetent individuals in European countries or North America are 
asymptomatic (Montoya and Liesenfeld, 2004). In the symptomatic infections, 
enlarged lymph nodes are commonly observed. Lymphadenopathy is often 
associated with fever, fatigue, muscle pain, sore throat and headache (Hill and 
Dubey, 2002). Less commonly, the acute acquired infection causes toxoplasmic 
chorioretinitis with visual impairment (Delair et al., 2008). Bowie et al. (1997) found 
that 51 out of 100 individuals infected with toxoplasmosis during an outbreak had 
lymphadenopathy while 19 of the remaining individuals had retinitis. Acquired 
toxoplasmosis was reported to be responsible for 23.5% of 425 cases of ocular 
toxoplasmosis (Delair et al., 2008). Other common symptoms of acquired 
toxoplasmosis include stiff neck, poor appetite, joint pain, rash, confusion, nausea, 
eye pain and abdominal pain. Pneumonia and nephritis were also reported (Canon-
Franco et al., 2014). Table 1.1 shows the frequency of symptoms in 
immunocompetent people reported from several toxoplasmosis outbreaks.  
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Table 1.1 Frequency of symptoms in immunocompetent people with acquired 
toxoplasmosis (Dubey, 2009). 
Symptoms 
Patients with symptoms (%) 
Atlanta, USA 
outbreak (35 
patients) 
Panama outbreak
 
(35 patients) 
Parána outbreak 
(155 patients) 
Fever 94 90 82 
Lymphadenopathy 88 77 75 
Headache 88 77 87 
Myalgia 63 68 80 
Stiff neck 57 55 NR 
Anorexia 57 NR 69 
Sore throat 46 NR NR 
Arthralgia 26 29 61 
Rash 23 0 7 
Confusion 20 NR NR 
Earache 17 NR NR 
Nausea 17 36 38 
Eye pain 14 26 NR 
Abdominal pain 11 55 NR 
* NR: not reported  
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1.9.2 Congenital toxoplasmosis 
Congenital toxoplasmosis from primary acquired maternal infection during 
the first trimester of gestation often causes severe consequences such as abortion, 
stillbirth or infant abnormalities compared to maternal-fetal transmission during the 
second and third trimesters. Fetal infection at the second trimester can be of variable 
severities while the infection at third trimester is usually less severe.  
The multiplication of T. gondii induces necrosis foci and inflammation 
reactions, leading to infant abnormalities in brain and eye tissues. The most common 
symptoms of congenital toxoplasmosis among infants are retinochoroiditis and 
intracranial abnormalities with or without developmental delay (Gilbert et al., 2006). 
Other severe clinical manifestations of congenital toxoplasmosis include mental 
retardation, seizures, microcephalus, hydrocephalus, intracranial calcification, 
encephalitis, deafness, extensive cerebral destruction, psychomotor deficiency, 
convulsion and eye lesions  (Frenkel, 1974; McAuley et al., 1994; Swisher et al., 
1994). Severe eye lesions are observed in congenital toxoplasmosis at early 
pregnancy, this included microphthalmia, cataract, increased intraocular pressure, 
strabismus, optic neuritis and retinal necrosis (Roberts et al., 2001b; Delair et al., 
2011).  
Infants with congenital toxoplasmosis may have obvious systemic 
manifestation such as fever, hypothermia, jaundice, hepatosplenomegaly, diarrhea, 
vomit, lymphadenopathy, pneumonitis, myocarditis and petechial or purpuric rash 
(McAuley et al., 1994; Schwartzman, 2001). Meanwhile, the classical triad of 
chorioretinitis, hydrocephalus, and cerebral calcifications is uncommon as these 
symptoms are present in less than 10% of infected infants (Montoya and Liesenfeld, 
2004). 
 24 
 
Approximately 75% of infants born with toxoplasmosis are asymptomatic but 
subsequently, develop clinical symptoms within months to years (Schwartzman, 
2001). Phan et al. (2008) reported that 72% of 25 congenitally infected infants 
developed eye lesions during a mean follow-up of 5.7 years. Freeman et al. (2008) 
also reported 50 ocular diseases and 17 recurrent retinochoroiditis developed out of 
281 children with congenital toxoplasmosis in a median follow-up of 4.1 years. 
Table 1.2 shows clinical presentation in untreated congenital toxoplasmosis patients 
at birth and with follow-up of four years and more.  
 
1.9.3 Immunocompromised patients  
Acute or reactivated T. gondii infection causes serious life-threatening 
diseases in immunocompromised patients. The immunocompromised groups with 
increased risk of developing toxoplasmosis include transplantation patients who are 
treated with immunosuppressive agents, cancer patients with low immunity and 
acquired immunodeficiency syndrome (AIDS) patients. The most common 
manifestation of toxoplasmosis seen in immunocompromised patients is encephalitis 
(Hill and Dubey, 2002). Besides, the heart and lungs of an immunocompromised 
patient can also be infected.  
The clinical symptoms of toxoplasmosis reported in organ transplantation 
include febrile myocarditis, encephalitis or pneumonitis. The symptoms can be 
observed as early as two weeks but are commonly seen within the first three months 
after the transplantation (Derouin et al., 2008). The mortality rates of organ 
transplantation patients who developed toxoplasmosis are high.  
 
 
